Elutia (ELUT) Expected to Post Quarterly Earnings on Thursday

Elutia (NASDAQ:ELUT) will likely be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Elutia to announce earnings of ($0.15) per share and revenue of $1.00 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Elutia (NASDAQ:ELUT) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The firm had revenue of $2.43 million during the quarter, compared to analysts’ expectations of $2.90 million. Elutia had a net margin of 426.93% and a negative return on equity of 407.37%.

Elutia Trading Up 2.8%

Shares of Elutia stock traded up $0.02 during trading on Tuesday, reaching $0.84. The company’s stock had a trading volume of 27,688 shares, compared to its average volume of 164,567. The company has a 50-day moving average price of $0.83 and a two-hundred day moving average price of $0.97. Elutia has a fifty-two week low of $0.50 and a fifty-two week high of $1.39. The firm has a market cap of $37.38 million, a PE ratio of 0.89 and a beta of 0.84.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Elutia from a “sell (d)” rating to a “sell (e+)” rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, Elutia presently has a consensus rating of “Sell”.

Elutia Company Profile

Elutia Inc is a medical technology company focused on developing and commercializing biologic products designed to support tissue healing and improve the performance of implantable medical devices. The company combines human tissue-based materials with drug-delivery and regenerative medicine technologies.

Its product portfolio includes biologic envelopes used to protect and support cardiac implantable electronic devices, including pacemakers and defibrillators. Elutia also develops tissue matrices and other biologic products for orthopedic, wound care and related surgical applications, with products intended to support soft-tissue repair, reconstruction and healing.

The company was formerly known as Aziyo Biologics and adopted the Elutia name as part of its broader focus on bioelectronic medicine and regenerative healthcare.